Follow
'The majority (68%) of the candidates are being developed independently or collaboratively by private companies/industry, while 25% are being developed by academic or other non-profit organizations (Fig. 2b). Notably, candidates against HIV and malaria are being developed mostly by academic or other non-profit organizations.'
